Humana Inc (HUM) Valuation

The primary valuation tool in the framework is a DCF analysis, but the provided GoodMoat Target of $2,380.35 is clearly inconsistent with the current price of $173 and the company's financials, suggesting a data error. A valid margin of safety cannot be calculated from this figure. Instead, we must rely on relative valuation. The forward P/E of 17.6x is below the typical healthcare sector average, which often sits in the low-to-mid 20s, and is likely below the stock's own historical average given its past growth rates. This suggests the market is not pricing in premium expectations. However, context is critical. The framework states a P/E of 25-26x can be reasonable for a 50% grower but high for a 10% grower. Humana's revenue growth of 11.3% is solid but not exceptional, and its profit margin of 0.9% and ROE of 6.7% indicate low current profitability and returns. The P/E multiple, while seemingly low, may be appropriate given these quality metrics. The FCF yield of 1.9% (implying a P/FCF of ~53x) is not favourable, and the debt/equity of 0.72 is manageable but not a net cash position. Overall, the stock appears cheap on a surface-level P/E comparison but is fairly valued or slightly unfavourable when assessed against its underlying quality and growth, as per the framework's principle that valuation must be relative to the business's fundamental strength. Analysis based on data as of 2024-05-15.